Previse, formerly known as Capsulomics, announced that the company has closed a $3 million seed round and launched its first laboratory-developed test, Esopredict™.

The seed round included participation from TEDCO, Wexford Science and Technology, Riptide Ventures, Gaingels, and numerous angel investors.

Previse is on a mission to save lives through the earlier detection and prevention of cancer, starting with esophageal cancer. They are actively working to get patients and healthcare providers the answers they need sooner by understanding and unlocking the power of biomarkers on cancer development and severity. Previse's technology was made possible by grants from the National Institutes of Health and developed after decades of research by the GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine.